Antiobesity Medications: Expert Discusses Older, Newer Therapies

Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD

News

Video

Obesity specialist Sandra Christensen, MSN, ARNP, details the differences between older antiobesity medications and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

How do older antiobesity medications, such as bupropion/naltrexone, phentermine/topirimate, and orlistat differ from the more recently approved GLP-1RAs liraglutide and semaglutide 2.4 mg?

Was a question Patient Care Online asked medical weight management specialist Sandra Christensen, MSN, ARNP, in a recent interview on antiobesity medications.

In the video below, Ms Christensen gives a primer on common antiobesity medications and discusses the differences between older antiobesity medications and newer GLP-1RA therapies.

Related Content

September 2nd 2025

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

August 28th 2025

Generic Liraglutide Approved, Marking First Generic GLP-1 RA Indicated Specifically for Weight Management in the US

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

August 29th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.

August 30th 2023

Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

What Do Individuals With Obesity Want in an "Ideal" Primary Care Visit?

Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.

What Do Individuals With Obesity Want in am "Ideal" Primary Care Visit? image credit ©Coloures-Pic/stock.adobe.com

Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD

People with obesity may shun basic primary care for fear of shaming, lectures, inhospitable equipment, and simple lack of respect from clinicians, authors found.

Related Content

September 2nd 2025

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

August 28th 2025

Generic Liraglutide Approved, Marking First Generic GLP-1 RA Indicated Specifically for Weight Management in the US

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

August 29th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.

August 30th 2023

Lilly’s Oral GLP-1 Orforglipron Meets End Points in Phase 3 Obesity and Diabetes Trial

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

What Do Individuals With Obesity Want in an "Ideal" Primary Care Visit?

Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.